What changed in this filing

/stocks — the workspaceLOADING

Item 2. Management’s Discussion and Analysis

2022-08-15 compared with 2022-05-16 · 285 added, 297 removed, 24 unchanged (96% of the section changed)

MANAGEMENT’S DISCUSSION AND

ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

References in this report (the

“Quarterly Report”) to “we,” “us” or the “Company” refer to AGBA Acquisition

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

in this report (the “Quarterly Report”) to “we,” “us” or the “Company” refer to AGBA

Acquisition Limited.

References to our “management” or our “management team” refer to our officers and directors,

references to the “Sponsor” refer to AGBA Holding Limited.

The following discussion and analysis of the Company’s

financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial

statements and the notes thereto contained elsewhere in this Quarterly Report.

Certain information contained in the discussion and

analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Special Note Regarding Forward-Looking Statements

This Quarterly Report includes “forward-looking

statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act that are not historical

facts, and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected.

statements, other than statements of historical fact included in this Form 10-Q including, without limitation, statements in this “Management’s

Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business

strategy and the plans and objectives of management for future operations, are forward-looking statements.

Words such as “expect,”

“believe,” “anticipate,” “intend,” “estimate,” “seek” and variations and

similar words and expressions are intended to identify such forward-looking statements.

Such forward-looking statements relate to future

events or future performance, but reflect management’s current beliefs, based on information currently available.

A number of factors

could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking

For information identifying important factors that could cause actual results to differ materially from those anticipated

in the forward-looking statements, please refer to the Risk Factors section of the Company’s registration statement on Form S-1

filed with the U.S.

Securities and Exchange Commission (the “SEC”).

The Company’s securities filings can be accessed

on the EDGAR section of the SEC’s website at www.sec.gov.

Except as expressly required by applicable securities law, the Company

disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future

events or otherwise.

We are a blank check company incorporated in

the British Virgin Islands on October 8, 2018 and formed for the purpose of entering into a merger, share exchange, asset acquisition,

share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.

We presently have no revenue, have had losses

since inception from incurring formation costs and have had no operations other than the active solicitation of a target business with

which to complete a business combination.

We have relied upon the sale of our securities and loans from our officers and directors to

fund our operations.

The following discussion and analysis of the Company’s financial

condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and

the notes thereto contained elsewhere in this Quarterly Report.

Certain information contained in the discussion and analysis set forth

below includes forward-looking statements that involve risks and uncertainties.

Note Regarding Forward-Looking Statements

Quarterly Report includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and

Section 21E of the Exchange Act that are not historical facts, and involve risks and uncertainties that could cause actual results to

differ materially from those expected and projected.

All statements, other than statements of historical fact included in this Form 10-Q

including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and Results

of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management for

future operations, are forward-looking statements.

Words such as “expect,” “believe,” “anticipate,”

“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify

such forward-looking statements.

Such forward-looking statements relate to future events or future performance, but reflect management’s

current beliefs, based on information currently available.

A number of factors could cause actual events, performance or results to differ

materially from the events, performance and results discussed in the forward-looking statements.

For information identifying important

factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to

the Risk Factors section of the Company’s registration statement on Form S-1 filed with the U.S.

Securities and Exchange Commission

The Company’s securities filings can be accessed on the EDGAR section of the SEC’s website at www.sec.gov.

Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any

forward-looking statements whether as a result of new information, future events or otherwise.

are a blank check company incorporated in the British Virgin Islands on October 8, 2018 and formed for the purpose of entering into a

merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one

or more businesses or entities.

presently have no revenue, have had losses since inception from incurring formation costs and have had no operations other than the active

solicitation of a target business with which to complete a business combination.

We have relied upon the sale of our securities and loans

from our officers and directors to fund our operations.

May 16, 2019, the Company consummated its initial public offering of 4,600,000 units, which includes the full exercise of the over-allotment

12 unchanged sentences

costs, including $2,175,948 of underwriting fees and $383,781 of initial public offering costs.

We will not issue fractional shares.

one must (1) exercise warrants in multiples of two warrants, at a price of $11.50 per full share, to validly exercise the warrants;

(2) hold rights in multiples of 10 in order to receive shares for all of the rights upon closing of a business combination.

On each of May 11, August 13 and November 10,

2020, we issued a $460,000 unsecured promissory note to the Sponsor, pursuant to which such amount was deposited into our Trust Account

in order to extend the amount of time we had available to complete a business combination from May 16, 2020 to February 16, 2021.

of February 10, May 11 and August 11, 2021, the Company issued an unsecured promissory note, in an amount of $594,467, to the Sponsor,

pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available time to complete a

business combination until November 16, 2021.

On each of November 10, 2021 and February 7, 2022, the Company issued an unsecured promissory

will not issue fractional shares.

As a result, one must (1) exercise warrants in multiples of two warrants, at a price of $11.50 per

full share, to validly exercise the warrants;

and (2) hold rights in multiples of 10 in order to receive shares for all of the rights

upon closing of a business combination.

each of May 11, August 13 and November 10, 2020, we issued a $460,000 unsecured promissory note to the Sponsor, pursuant to which such

amount was deposited into our Trust Account in order to extend the amount of time we had available to complete a business combination

from May 16, 2020 to February 16, 2021.

On each of February 10, May 11 and August 11, 2021, the Company issued an unsecured promissory

note, in an amount of $594,467, to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend

the amount of available time to complete a business combination until May 16, 2022.

Each of these promissory notes is non-interest bearing

and is payable upon the closing of a business combination.

In addition, each of the promissory notes may be converted, at the lender’s

discretion, into additional Private Units at a price of $10.00 per unit.

We held our annual meeting of shareholders on

May 3, 2022 (the “2022 Annual Meeting”).

During the 2022 Annual Meeting, shareholders approved, among other things, (i) the

Fourth Amended and Restated Memorandum and Articles of Association to extend the date by which the Company has to consummate a business

combination two times for three additional months each time from May 16, 2022 to November 16, 2022;

(ii) an amendment to the Company’s

investment management trust agreement, dated May 14, 2019, as amended, by and between the Company and Continental Stock Transfer &

Trust Company to extend the time to complete a business combination to November 16, 2022;

and (iii) elected all of the five nominees for

directors to serve until the next annual meeting of shareholders approved.

On May 9, 2022, we issued an unsecured promissory note, in

an amount of $504,431 to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount

of available time to complete a business combination until August 16, 2022.

Our management has broad discretion with respect

to the specific application of the net proceeds of the initial business combination and the private placement, although substantially

all of the net proceeds are intended to be applied generally towards consummating a business combination.

The outbreak of the COVID-19 coronavirus has

resulted in a widespread health crisis that has adversely affected the economies and financial markets worldwide, and potential target

companies may defer or end discussions for a potential business combination with us whether or not COVID-19 affects their business operations.

The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which are highly uncertain

and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19

or treat its impact, among others.

We may be unable to complete a business combination if continued concerns relating to COVID-19 restrict

travel, limit the ability to have meetings with potential investors or the target company’s personnel, vendors and services providers

are unavailable to negotiate and consummate a transaction in a timely manner.

On November 3, 2021, the Company entered into

the business combination Agreement, which provides for a business combination between AGBA and TAG and certain of TAG’s wholly owned

subsidiaries – OPH, Fintech, B2B, B2BSub, and HKSub.

OPH through its wholly-owned subsidiaries, is engaged in business-to-business

(or B2B) services, while Fintech through its wholly-owned subsidiaries, is engaged in the financial technology or fintech business.

is a wholly-owned subsidiary of B2B, and HKSub is a wholly owned subsidiary of B2BSub.

In the business combination agreement, as amended,

B2B, B2BSub, HKSub, OPH, Fintech, together with their respective subsidiaries are referred to as the “Group Parties”.

to the business combination agreement, as amended, OPH will first become a subsidiary of B2B through a merger with HKSub, with OPH as

the surviving entity (the “OPH Merger”).

Subsequently, (i) AMSI will merge with and into B2B;

and AMSII will merge with and

into Fintech (together with (i), the “Acquisition Merger”).

In consideration of the Acquisition Merger, AGBA will issue 55,500,000

ordinary shares with a deemed price per share US$10.00 (“Aggregate Stock Consideration”) to TAG, in its capacity as sole shareholder

of B2B and Fintech.

At the closing of the Acquisition Merger, AGBA

shall issue the full amount of the Aggregate Stock Consideration, less three percent (3%) of the Aggregate Stock Consideration (the “Holdback

Shares”), to TAG, in its capacity as sole shareholder of B2B and Fintech, subject to compliance with applicable law.

the provisions of the business combination Agreement, AGBA will release the Holdback Shares at the end of six (6) months following the

closing of the Acquisition Merger, which may be extended for an additional three-month period (the “Survival Period”), provided

that the AGBA will be entitled to retain some or all of the Holdback Shares to satisfy certain indemnification claims during the Survival

Post-closing, TAG intends to further distribute the Aggregate Stock Consideration to certain beneficial shareholders of TAG, subject

to legal and regulatory requirements.

Results of Operations

Our entire activity from inception up to May 16,

2019 was in preparation for the initial public offering.

Since the initial public offering, our activity has been limited to the evaluation

of business combination candidates and engaging in activities in connection with the proposed business combination transaction with TAG,

and we will not be generating any operating revenues until the closing and completion of our business combination.

For the three months ended March 31, 2022, we

had a net loss of $351,736, which was comprised of interest and dividend income and general and administrative expenses, as well as a

loss from the change in fair value of warrant liabilities.

For the three months ended March 31, 2021, we

had a net loss of $131,804, which was comprised of general and administrative expenses and a loss from change in fair value of warrant

the amount of available time to complete a business combination until November 16, 2021.

On each of November 10, 2021 and February 7,

2022, the Company issued an unsecured promissory note in an amount of $546,991, to the Sponsor, pursuant to which such amount had been

deposited into the Trust Account in order to extend the amount of available time to complete a business combination until May 16, 2022.

Each of these promissory notes is non-interest bearing and is payable upon the closing of a business combination.

In addition, each of

the promissory notes may be converted, at the lender’s discretion, into additional Private Units at a price of $10.00 per unit.

held our annual meeting of shareholders on May 3, 2022 (the “2022 Annual Meeting”).

During the 2022 Annual Meeting,

shareholders approved, among other things, (i) the Fourth Amended and Restated Memorandum and Articles of Association to extend the

date by which the Company has to consummate a business combination two times for three additional months each time from May 16, 2022

to November 16, 2022;

(ii) an amendment to the Company’s investment management trust agreement, dated May 14, 2019, as

amended, by and between the Company and Continental Stock Transfer & Trust Company to extend the time to complete a business

combination to November 16, 2022;

and (iii) elected all of the five nominees for directors to serve until the next annual meeting of

shareholders approved.

On each of May 9, 2022, and August 9, 2022, we issued an unsecured promissory note, in an amount of $504,431

to the Sponsor, pursuant to which such amount had been deposited into the Trust Account in order to extend the amount of available

time to complete a business combination until November 16, 2022.

management has broad discretion with respect to the specific application of the net proceeds of the initial business combination and

the private placement, although substantially all of the net proceeds are intended to be applied generally towards consummating a business

outbreak of the COVID-19 coronavirus has resulted in a widespread health crisis that has adversely affected the economies and financial

markets worldwide, and potential target companies may defer or end discussions for a potential business combination with us whether or

not COVID-19 affects their business operations.

The extent to which COVID-19 impacts our search for a business combination will depend

on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the

severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.

We may be unable to complete a business combination

if continued concerns relating to COVID-19 restrict travel, limit the ability to have meetings with potential investors or the target

company’s personnel, vendors and services providers are unavailable to negotiate and consummate a transaction in a timely manner.

November 3, 2021, the Company entered into the business combination Agreement, which provides for a business combination between AGBA

and TAG and certain of TAG’s wholly owned subsidiaries – OPH, Fintech, B2B, B2BSub, and HKSub.

OPH through its wholly-owned

subsidiaries, is engaged in business-to-business (or B2B) services, while Fintech through its wholly-owned subsidiaries, is engaged in

the financial technology or fintech business.

B2BSub is a wholly-owned subsidiary of B2B, and HKSub is a wholly owned subsidiary of B2BSub.

In the business combination agreement, as amended, B2B, B2BSub, HKSub, OPH, Fintech, together with their respective subsidiaries are

referred to as the “Group Parties”.

Pursuant to the business combination agreement, as amended, OPH will first become a subsidiary

of B2B through a merger with HKSub, with OPH as the surviving entity (the “OPH Merger”).

Subsequently, (i) AMSI will merge

with and into B2B;

and AMSII will merge with and into Fintech (together with (i), the “Acquisition Merger”).

In consideration

of the Acquisition Merger, AGBA will issue 55,500,000 ordinary shares with a deemed price per share US$10.00 (“Aggregate Stock

Consideration”) to TAG, in its capacity as sole shareholder of B2B and Fintech.

the closing of the Acquisition Merger, AGBA shall issue the full amount of the Aggregate Stock Consideration, less three percent (3%)

of the Aggregate Stock Consideration (the “Holdback Shares”), to TAG, in its capacity as sole shareholder of B2B and Fintech,

subject to compliance with applicable law.

Subject to the provisions of the business combination Agreement, AGBA will release the Holdback

Shares at the end of six (6) months following the closing of the Acquisition Merger, which may be extended for an additional three-month

period (the “Survival Period”), provided that the AGBA will be entitled to retain some or all of the Holdback Shares to satisfy

certain indemnification claims during the Survival Period.

Post-closing, TAG intends to further distribute the Aggregate Stock Consideration

to certain beneficial shareholders of TAG, subject to legal and regulatory requirements.

of Operations

entire activity from inception up to May 16, 2019 was in preparation for the initial public offering.

Since the initial public offering,

our activity has been limited to the evaluation of business combination candidates and engaging in activities in connection with the

proposed business combination transaction with TAG, and we will not be generating any operating revenues until the closing and completion

of our business combination.

the three months ended June 30, 2022, we had a net loss of $231,350, which was comprised of dividend income and general and administrative

expenses, as well as a loss from the change in fair value of warrant liabilities.

the three months ended June 30, 2021, we had a net loss of $174,441, which was comprised of general and administrative expenses and a

loss from change in fair value of warrant liabilities.

the six months ended June 30, 2022, we had a net loss of $583,086, which was comprised of interest and dividend income and general and

administrative expenses, as well as a loss from the change in fair value of warrant liabilities.

the six months ended June 30, 2021, we had a net loss of $306,245, which was comprised of general and administrative expenses and a loss

from change in fair value of warrant liabilities.

and Capital Resources

As of March 31, 2022, we had cash of $33,356 outside

our Trust Account available for working capital needs.

All remaining cash was held in the Trust Account and is generally unavailable for

our use, prior to the business combination.

On May 16, 2019, we consummated the initial public

offering of 4,600,000 Public Units (which includes the full exercise of the underwriter’s over-allotment option), at a price of

$10.00 per unit, generating gross proceeds of $46,000,000.

Simultaneously with the closing of the initial public offering, we consummated

the sale of 225,000 Private Units, at a price of $10.00 per unit, generating gross proceeds of $2,250,000.

Following the initial public offering and the

exercise of the over-allotment option, a total of $46,000,000 was placed in the Trust Account.

We incurred $2,559,729 in initial public

offering related costs, including $2,175,948 of underwriting fees and $383,781 of initial public offering costs.

Our liquidity needs have been satisfied to date

through receipt of $25,000 from the sale of the insider shares, advances from our Sponsor in an aggregate amount of $1,157,787 outstanding

as of March 31, 2022, and the remaining net proceeds from our initial public offering and private placement.

We intend to use substantially all of the net

proceeds of the initial public offering, including the funds held in the Trust Account, to acquire a target business or businesses and

to pay our expenses relating thereto.

To the extent that our capital stock is used in whole or in part as consideration to effect our

business combination, the remaining proceeds held in the Trust Account, as well as any other net proceeds not expended, will be used

as working capital to finance the operations of the target business.

Such working capital funds could be used in a variety of ways including

continuing or expanding the target business’ operations, for strategic acquisitions and for marketing, research and development

of existing or new products.

Such funds could also be used to repay any operating expenses or finders’ fees which we had incurred

prior to the completion of our business combination if the funds available to us outside of the Trust Account were insufficient to cover

such expenses.

We intend to use the funds held outside the Trust

Account primarily for activities relating to consummating the proposed business combination with TAG.

If our estimates of the costs of consummating

our proposed business combination is less than the actual amount necessary to do so, or the amount of interest available to us from the

Trust Account is less than we expect as a result of the current interest rate environment, we may have insufficient funds available to

operate our business prior to our initial business combination.

Moreover, we may need to obtain additional financing either to consummate

our initial business combination or because we become obligated to redeem a significant number of our public shares upon consummation

of our initial business combination, in which case we may issue additional securities or incur debt in connection with such business combination.

Subject to compliance with applicable securities laws, we would only consummate such financing simultaneously with the consummation of

our initial business combination.

Following our initial business combination, if cash on hand is insufficient, we may need to obtain additional

financing in order to meet our obligations, and there is no assurance that such financing can be obtained on favorable terms, or at all.

We may need to seek additional capital through

loans or additional investments from members of our management team, but such members of our management team are not under any obligation

to advance funds to, or invest in, us.

In the event that the business combination does not close, we may use a portion of the working

capital held outside the Trust Account to repay such loaned amounts, but no proceeds from our Trust Account would be used for such repayment.

of June 30, 2022, we had cash of $85,619 outside our Trust Account available for working capital needs.

All remaining cash was held in

the Trust Account and is generally unavailable for our use, prior to the business combination.

May 16, 2019, we consummated the initial public offering of 4,600,000 Public Units (which includes the full exercise of the underwriter’s

over-allotment option), at a price of $10.00 per unit, generating gross proceeds of $46,000,000.

Simultaneously with the closing of the

initial public offering, we consummated the sale of 225,000 Private Units, at a price of $10.00 per unit, generating gross proceeds of

the initial public offering and the exercise of the over-allotment option, a total of $46,000,000 was placed in the Trust Account.

incurred $2,559,729 in initial public offering related costs, including $2,175,948 of underwriting fees and $383,781 of initial public

offering costs.

liquidity needs have been satisfied to date through receipt of $25,000 from the sale of the insider shares, note payable of $4,761,812

and advances from our Sponsor in an aggregate amount of $1,419,337 outstanding as of June 30, 2022, and the remaining net proceeds from

our initial public offering and private placement.

intend to use substantially all of the net proceeds of the initial public offering, including the funds held in the Trust Account, to

acquire a target business or businesses and to pay our expenses relating thereto.

To the extent that our capital stock is used in whole

or in part as consideration to effect our business combination, the remaining proceeds held in the Trust Account, as well as any other

net proceeds not expended, will be used as working capital to finance the operations of the target business.

Such working capital funds

could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic acquisitions

and for marketing, research and development of existing or new products.

Such funds could also be used to repay any operating expenses

or finders’ fees which we had incurred prior to the completion of our business combination if the funds available to us outside

of the Trust Account were insufficient to cover such expenses.

intend to use the funds held outside the Trust Account primarily for activities relating to consummating the proposed business combination

our estimates of the costs of consummating our proposed business combination is less than the actual amount necessary to do so, or the

amount of interest available to us from the Trust Account is less than we expect as a result of the current interest rate environment,

we may have insufficient funds available to operate our business prior to our initial business combination.

Moreover, we may need to

obtain additional financing either to consummate our initial business combination or because we become obligated to redeem a significant

number of our public shares upon consummation of our initial business combination, in which case we may issue additional securities or

incur debt in connection with such business combination.

Subject to compliance with applicable securities laws, we would only consummate

such financing simultaneously with the consummation of our initial business combination.

Following our initial business combination,

if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations, and there is no assurance

that such financing can be obtained on favorable terms, or at all.

may need to seek additional capital through loans or additional investments from members of our management team, but such members of

our management team are not under any obligation to advance funds to, or invest in, us.

In the event that the business combination does

not close, we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts, but no proceeds from

our Trust Account would be used for such repayment.

Such loans would be evidenced by promissory notes.

The notes would either be paid upon consummation of our business combination, without

interest, or, at the lender’s discretion, up to $500,000 of the notes may be converted upon consummation of our business combination

into additional Private Units at a price of $10.00 per unit.

The terms of such loans by our initial shareholders, officers and directors,

if any, have not been determined and no written agreements exist with respect to such loans.

Accordingly, the Company may not be able to obtain

additional financing.

If the Company is unable to raise additional capital, it may be required to take additional measures to conserve

liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction,

and reducing overhead expenses.

The Company cannot provide any assurance that new financing will be available to it on commercially acceptable

terms, if at all.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern if a business

combination is not consummated by August 16, 2022.

These unaudited condensed consolidated financial statements do not include any adjustments

relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be

unable to continue as a going concern.

Off-balance Sheet Financing Arrangements

We have no obligations, assets or liabilities

which would be considered off-balance sheet arrangements as of March 31, 2022.

We do not participate in transactions that create relationships

with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established

for the purpose of facilitating off-balance sheet arrangements.

We have not entered into any off-balance sheet financing arrangements,

established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.

Contractual Obligations

We do not have any long-term debt, capital lease

obligations, operating lease obligations or long-term liabilities other than an agreement to pay our Sponsor a monthly fee of $10,000

for general and administrative services, including office space, utilities and administrative services to the Company.

We began incurring

these fees on May 16, 2019 and will continue to incur these fees monthly until the earlier of the completion of the business combination

and the Company’s liquidation.

The notes would either be paid

upon consummation of our business combination, without interest, or, at the lender’s discretion, up to $500,000 of the notes may

be converted upon consummation of our business combination into additional Private Units at a price of $10.00 per unit.

such loans by our initial shareholders, officers and directors, if any, have not been determined and no written agreements exist with

respect to such loans.

the Company may not be able to obtain additional financing.

If the Company is unable to raise additional capital, it may be required

to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending

the pursuit of a potential transaction, and reducing overhead expenses.

The Company cannot provide any assurance that new financing will

be available to it on commercially acceptable terms, if at all.

These conditions raise substantial doubt about the Company’s ability

to continue as a going concern if a business combination is not consummated by November 16, 2022.

These unaudited condensed consolidated

financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities

that might be necessary should the Company be unable to continue as a going concern.

Sheet Financing Arrangements

have no obligations, assets or liabilities which would be considered off-balance sheet arrangements as of June 30, 2022.

We do not participate

in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest

entities, which would have been established for the purpose of facilitating off-balance sheet arrangements.

We have not entered into

any off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities,

or purchased any non-financial assets.

do not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities other than an agreement

to pay our Sponsor a monthly fee of $10,000 for general and administrative services, including office space, utilities and administrative

services to the Company.

We began incurring these fees on May 16, 2019 and will continue to incur these fees monthly until the earlier

of the completion of the business combination and the Company’s liquidation.

Also, we are committed to the below:

Registration Rights

The holders of our insider shares issued and

outstanding prior to our initial public offering, as well as the holders of the Private Units (and all underlying securities) and any

securities our initial shareholders, officers, directors or their affiliates may be issued in payment of working capital loans made to

us, are entitled to registration rights pursuant to a registration rights agreement entered into concurrently without initial public

In addition, the holders have certain “piggy-back” registration rights with respect to registration statements

filed subsequent to our consummation of a business combination.

We will bear the expenses incurred in connection with the filing of any

such registration statements.

Underwriting Agreement

The underwriter is entitled to a cash underwriting

discount of six and half percent (6.5%), or $0.65 per unit, of the gross proceeds of the initial public offering.

Two and one-half percent

(2.5%), or $0.25 per share, is not contingent and has been paid at the closing of the initial public offering.

Four percent (4.0%), or

$0.40 per unit, is contingent on the closing of a business combination and will be deferred by the underwriters and be placed in the

Trust Account.

Such deferred amount will only be payable to the underwriters upon closing of a business combination.

Further, the deferred

amount paid to the underwriters upon the closing of a business combination will be reduced by two percent (2.0%), or $0.20 per unit,

for each unit that is redeemed by shareholders in connection with the business combination.

If the business combination is not consummated,

the deferred amount will be forfeited by the underwriters.

The underwriters will not be entitled to any interest accrued on the deferred

Private Warrants

The Company classifies the private warrants as

liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.

This liability is subject to

re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations.

holders of our insider shares issued and outstanding prior to our initial public offering, as well as the holders of the Private Units

(and all underlying securities) and any securities our initial shareholders, officers, directors or their affiliates may be issued in

payment of working capital loans made to us, are entitled to registration rights pursuant to a registration rights agreement entered

into concurrently without initial public offering.

In addition, the holders have certain “piggy-back” registration rights

with respect to registration statements filed subsequent to our consummation of a business combination.

We will bear the expenses incurred

in connection with the filing of any such registration statements.

underwriter is entitled to a cash underwriting discount of six and half percent (6.5%), or $0.65 per unit, of the gross proceeds of the

initial public offering.

Two and one-half percent (2.5%), or $0.25 per share, is not contingent and has been paid at the closing of the

initial public offering.

Four percent (4.0%), or $0.40 per unit, is contingent on the closing of a business combination and will be deferred

by the underwriters and be placed in the Trust Account.

Such deferred amount will only be payable to the underwriters upon closing of

a business combination.

Further, the deferred amount paid to the underwriters upon the closing of a business combination will be reduced

by two percent (2.0%), or $0.20 per unit, for each unit that is redeemed by shareholders in connection with the business combination.

If the business combination is not consummated, the deferred amount will be forfeited by the underwriters.

The underwriters will not

be entitled to any interest accrued on the deferred amount.

Company classifies the private warrants as liabilities at their fair value and adjusts the private warrants to fair value at each reporting

This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized

in our statement of operations.

The private warrants are valued using a Black Scholes model.

Unit Purchase Option

The Company sold to Maxim for $100, an option

to purchase 276,000 units exercisable, at $11.50 per unit, between the first and fifth anniversary of the effective date of the registration

statement relating to our initial public offering.

The purchase option may be exercised for cash or on a cashless basis, at the holder’s

option, and expires on May 13, 2024.

The Company accounted for the unit purchase option, inclusive of the receipt of $100 cash payment,

as an expense of the Public Offering resulting in a charge directly to shareholders’ equity.

The Company estimates that the fair

value of the unit purchase option is approximately $747,960, or $2.71 per Unit, using the Black-Scholes option-pricing model.

value of the unit purchase option granted to the underwriters is estimated as of the date of grant using the following assumptions:

expected volatility of 35%, (2) risk-free interest rate of 2.18% and (3) expected life of four years between first and fifth anniversary

dates of the Effective Date.

The option and the units, as well as the ordinary shares and warrants to purchase ordinary shares that may

be issued upon exercise of the option, have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of

180 days immediately following the effective date of the registration statement for our initial public offering pursuant to Rule 5110(g)(1)

of FINRA’s rules, during which time the option may not be sold, transferred, assigned, pledged or hypothecated, or be subject of

any hedging, short sale, derivative or put or call transaction that would result in the economic disposition of the securities.

Additionally,

the option may not be sold, transferred, assigned, pledged or hypothecated prior to May 13, 2020 except to any underwriters and selected

dealer participating in the offering and their bona fide officers or partners.

The option grants to holders demand and “piggy back”

rights for periods of five and seven years, respectively, from the effective date of the registration statement of which forms a part

with respect to the registration under the Securities Act of the securities directly and indirectly issuable upon exercise of the option.

We will bear all fees and expenses attendant to registering the securities, other than underwriting commissions which will be paid for

by the holders themselves.

The exercise price and number of units issuable upon exercise of the option may be adjusted in certain circumstances

including in the event of a share dividend, or our recapitalization, reorganization, merger or consolidation.

However, the option will

not be adjusted for issuances of ordinary shares at a price below its exercise price.

Right of First Refusal

Subject to certain conditions, the Company granted

Maxim, for a period of 18 months after the date of the consummation of the business combination, a right of first refusal to act as lead

underwriters or minimally as a co-manager, with at least 30% of the economics;

or, in the case of a three-handed deal, 20% of the economics,

for any and all future public and private equity and debt offerings.

In accordance with FINRA rule 5110(f)(2)(E)(i), such right of first

refusal shall not have a duration of more than three years from the effective date of the registration statement for our initial public

Critical Accounting Policies

The preparation of the unaudited condensed

consolidated financial statements and related disclosures in conformity with accounting principles generally accepted in the United

States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of

assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated

financial statements, and income and expenses during the periods reported.

Purchase Option

Company sold to Maxim for $100, an option to purchase 276,000 units exercisable, at $11.50 per unit, between the first and fifth anniversary

of the effective date of the registration statement relating to our initial public offering.

The purchase option may be exercised for

cash or on a cashless basis, at the holder’s option, and expires on May 13, 2024.

The Company accounted for the unit purchase option,

inclusive of the receipt of $100 cash payment, as an expense of the Public Offering resulting in a charge directly to shareholders’

The Company estimates that the fair value of the unit purchase option is approximately $747,960, or $2.71 per Unit, using the

Black-Scholes option-pricing model.

The fair value of the unit purchase option granted to the underwriters is estimated as of the date

of grant using the following assumptions:

(1) expected volatility of 35%, (2) risk-free interest rate of 2.18% and (3) expected life

of four years between first and fifth anniversary dates of the Effective Date.

The option and the units, as well as the ordinary shares

and warrants to purchase ordinary shares that may be issued upon exercise of the option, have been deemed compensation by FINRA and are

therefore subject to a lock-up for a period of 180 days immediately following the effective date of the registration statement for our

initial public offering pursuant to Rule 5110(g)(1) of FINRA’s rules, during which time the option may not be sold, transferred,

assigned, pledged or hypothecated, or be subject of any hedging, short sale, derivative or put or call transaction that would result

in the economic disposition of the securities.

Additionally, the option may not be sold, transferred, assigned, pledged or hypothecated

prior to May 13, 2020 except to any underwriters and selected dealer participating in the offering and their bona fide officers or partners.

The option grants to holders demand and “piggy back” rights for periods of five and seven years, respectively, from the effective

date of the registration statement of which forms a part with respect to the registration under the Securities Act of the securities

directly and indirectly issuable upon exercise of the option.

We will bear all fees and expenses attendant to registering the securities,

other than underwriting commissions which will be paid for by the holders themselves.

The exercise price and number of units issuable

upon exercise of the option may be adjusted in certain circumstances including in the event of a share dividend, or our recapitalization,

reorganization, merger or consolidation.

However, the option will not be adjusted for issuances of ordinary shares at a price below its

exercise price.

of First Refusal

to certain conditions, the Company granted Maxim, for a period of 18 months after the date of the consummation of the business combination,

a right of first refusal to act as lead underwriters or minimally as a co-manager, with at least 30% of the economics;

or, in the case

of a three-handed deal, 20% of the economics, for any and all future public and private equity and debt offerings.

In accordance with

FINRA rule 5110(f)(2)(E)(i), such right of first refusal shall not have a duration of more than three years from the effective date of

the registration statement for our initial public offering.

Accounting Policies

preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with accounting principles

generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect

the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the unaudited condensed

consolidated financial statements, and income and expenses during the periods reported.

Actual results could materially differ from those

The Company has not identified any significant accounting policies.

Ordinary Shares Subject To Possible Redemption

The Company accounts for its ordinary shares

subject to possible redemption in accordance with the guidance in ASC Topic 480 “ Distinguishing Liabilities from Equity .”

Ordinary share subject to mandatory redemption (if any) is classified as a liability instrument and is measured at fair value.

Conditionally

redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder

or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary

Shares Subject To Possible Redemption

Company accounts for its ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic 480 “ Distinguishing

Liabilities from Equity .” Ordinary share subject to mandatory redemption (if any) is classified as a liability instrument and

is measured at fair value.

Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are

either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s

control) are classified as temporary equity.

At all other times, ordinary shares are classified as shareholders’ equity.

The Company’s ordinary shares feature

certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future

Net Income (Loss) Per Share

The Company calculates net loss per share in

accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share is computed by dividing the net loss by

the weighted-average number of ordinary shares outstanding during the period, excluding ordinary shares subject to possible conversion.

Diluted loss per share is computed by dividing net loss by the weighted average number of ordinary shares outstanding, plus to the extent

dilutive, the incremental number of ordinary shares to settle rights and other ordinary share equivalents (currently none outstanding),

as calculated using the treasury stock method.

Ordinary shares subject to possible conversion at March 31, 2022, which are not currently

redeemable and are not redeemable at fair value, have been excluded from the calculation of basic and diluted loss per share since such

shares, if redeemed, only participate in their pro rata share of the Trust Account earnings.

The Company has not considered the effect

of rights that convert into 276,000 ordinary shares in the unit purchase option sold to the underwriter, in the calculation of diluted

loss per share, since the conversion of the rights into ordinary is contingent upon the occurrence of future events.

Warrant Liabilities

The Company accounts for the warrants in accordance

with the guidance contained in ASC 815-40-15-7D and 7F under which the private warrants do not meet the criteria for equity treatment

and must be recorded as liabilities.

Accordingly, the Company classifies the private warrants as liabilities at their fair value and adjusts

the private warrants to fair value at each reporting period.

This liability is subject to re-measurement at each balance sheet date until

exercised, and any change in fair value is recognized in our statement of operations.

The private warrants are valued using a Black Scholes

The Company’s

ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence

of uncertain future events.

Income (Loss) Per Share

Company calculates net loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic loss per share

is computed by dividing the net loss by the weighted-average number of ordinary shares outstanding during the period, excluding ordinary

shares subject to possible conversion.

Diluted loss per share is computed by dividing net loss by the weighted average number of ordinary

shares outstanding, plus to the extent dilutive, the incremental number of ordinary shares to settle rights and other ordinary share

equivalents (currently none outstanding), as calculated using the treasury stock method.

Ordinary shares subject to possible conversion

at June 30, 2022, which are not currently redeemable and are not redeemable at fair value, have been excluded from the calculation of

basic and diluted loss per share since such shares, if redeemed, only participate in their pro rata share of the Trust Account earnings.

The Company has not considered the effect of rights that convert into 276,000 ordinary shares in the unit purchase option sold to the

underwriter, in the calculation of diluted loss per share, since the conversion of the rights into ordinary is contingent upon the occurrence

of future events.

Company accounts for the warrants in accordance with the guidance contained in ASC 815-40-15-7D and 7F under which the private warrants

do not meet the criteria for equity treatment and must be recorded as liabilities.

Accordingly, the Company classifies the private warrants

as liabilities at their fair value and adjusts the private warrants to fair value at each reporting period.

This liability is subject

to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in our statement of operations.

The private warrants are valued using a Black Scholes model.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 2. Management’s Discussion and Analysis